Piet Ost

@piet_ost

Radiation Oncologist, Iridium Network, GZA Ziekenhuizen, Antwerp. Associate professor Ghent University, Belgium.

Gent, België

iridiumnetwork.be

Replies Reposts Media

Pinned
Piet Ost
@piet_ost
May 5, 2025
📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity
18
Piet Ost
@piet_ost
Aug 4
@EORTC and @TROGfightcancer working together to write a white paper on the importance of RTQA in every trial that has a radiotherapy component. @AitriumOS just made this a no brainer and treats RT just like another variable you collect and can control for.
Aitrium
@AitriumOS
Aug 3
Quality Matters. In every trial with radiation, the treatment plan is a variable too. Now, measuring it is no longer the hard part. aitriumos.com/?1
1
Piet Ost
@piet_ost
May 19
What a beautiful message at the end of @Mat_Guc presidency at #ESTRO26 passing the torch to @BarbaraJereczek! See you at #ESTRO27 in Milano, 21-25th of May 2027.
3
Piet Ost
@piet_ost
May 18
Agree with @drdavidpalma: if we pool data from SABR-COMET trials with OligoRare (@Mat_Guc), EXTEND Trials (@ChadTangMD) we will have sufficient data to see if there are histological differences that matter. Big effort coming from @jonas_willmann and @mchiels coming out soon 😊.
2
Piet Ost
@piet_ost
May 17
DART results: Darolutamide added to SBRT for PSMA PET recurrent mHSPC temporary improves PSA responses and MFS, with a temporary increase in hormonal G1-2 adverse events. Thank you to all the patients and Belgian collaborators. @ESTRO2026 @Bayer
4